dalteparin has been researched along with Spinal Diseases in 7 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Spinal Diseases: Diseases involving the SPINE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a randomised open study, 44 pregnant women with confirmed previous or current thromboembolism were randomised to receive either low-molecular-weight heparin, dalteparin (N = 21) once daily subcutaneously or unfractionated sodium heparin (UF heparin, N = 23) twice daily subcutaneously for thromboprophylaxis during pregnancy and puerperium." | 5.10 | Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. ( Hiilesmaa, V; Kaaja, R; Leinonen, P; Markkola, A; Pettilä, V, 2002) |
| " However, different LMWHs vary significantly in their pharmacokinetic profile and bioavailability pattern." | 2.70 | [Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients]. ( Bergauer, F; Hagena, FW; Janni, W; Lohscheidt, K; Rjosk, D, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gerlach, R | 1 |
| Raabe, A | 1 |
| Beck, J | 1 |
| Woszczyk, A | 1 |
| Seifert, V | 1 |
| Heppner, PA | 1 |
| Monteith, SJ | 1 |
| Law, AJ | 1 |
| Horlocker, TT | 1 |
| Wysowski, DK | 1 |
| Talarico, L | 1 |
| Bacsanyi, J | 1 |
| Botstein, P | 1 |
| Lilley, LL | 1 |
| Guanci, R | 1 |
| Janni, W | 1 |
| Bergauer, F | 1 |
| Rjosk, D | 1 |
| Lohscheidt, K | 1 |
| Hagena, FW | 1 |
| Pettilä, V | 1 |
| Leinonen, P | 1 |
| Markkola, A | 1 |
| Hiilesmaa, V | 1 |
| Kaaja, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients[NCT00669721] | 40 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Spinal Diseases
| Article | Year |
|---|---|
Spontaneous spinal hematomas and low-molecular-weight heparin. Report of four cases and review of the literature.
Topics: Aged; Anticoagulants; Cervical Vertebrae; Enoxaparin; Follow-Up Studies; Hematoma; Humans; Male; Mid | 2004 |
2 trials available for dalteparin and Spinal Diseases
| Article | Year |
|---|---|
[Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2001 |
Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Dalteparin; Factor Xa Inhibitors; Femal | 2002 |
4 other studies available for dalteparin and Spinal Diseases
| Article | Year |
|---|---|
Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery.
Topics: Adult; Aged; Anticoagulants; Bandages; Cohort Studies; Female; Hematoma; Hemorrhage; Humans; Laminec | 2004 |
Low-molecular-weight heparins.
Topics: Anesthesia, Epidural; Anesthesia, Spinal; Enoxaparin; Hematoma; Humans; Spinal Diseases; Thrombosis | 1998 |
Spinal and epidural hematoma and low-molecular-weight heparin.
Topics: Adult; Aged; Aged, 80 and over; Anesthesia, Epidural; Anesthesia, Spinal; Anticoagulants; Enoxaparin | 1998 |
Risking epidural hematoma.
Topics: Arthroplasty, Replacement, Hip; Enoxaparin; Epidural Space; Female; Fibrinolytic Agents; Hematoma; H | 1998 |